Download Publications, 2005

Publications, 2005
Department of Oncology, Lund University Hospital, Lund
1.
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M.,
Borg A., Mitelman F., Johansson B., Hoglund M. and Fioretos T. Gene expression
profiling of leukemic cell lines reveals conserved molecular signatures among
subtypes with specific genetic aberrations. Leukemia 2005 Apr 21.
2.
Antoniou A. C., Pharoah P. D., Narod S., Risch H. A., Eyfjord J. E., Hopper J. L.,
Olsson H., Johannsson O., Borg A., Pasini B., Radice P., Manoukian S., Eccles D. M.,
Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B.,
Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjakoski K., Kallioniemi O. P.,
Thompson D., Evans C., Peto J., Lalloo F., Evans D. G. and Easton D. F. Breast and
ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2
6174delT mutations: a combined analysis of 22 population based studies. J Med
Genet 2005;42(7):602-3 Jul.
3.
Aschim E. L., Giwercman A., Stahl O., Eberhard J., Cwikiel M., Nordenskjold A.,
Haugen T. B., Grotmol T. and Giwercman Y. L. The RsaI polymorphism in the
ER{beta} gene is associated with male infertility. J Clin Endocrinol Metab 2005 Jul
5.
4.
Ask A., Bjork-Eriksson T., Zackrisson B., Blomquist E. and Glimelius B. The
potential of proton beam radiation therapy in head and neck cancer. Acta Oncol
2005;44(8):876-80
5.
Ask A., Johansson B. and Glimelius B. The potential of proton beam radiation therapy
in gastrointestinal cancer. Acta Oncol 2005;44(8):896-903
6.
Belting M., Ahamed J. and Ruf W. Signaling of the Tissue Factor Coagulation
Pathway in Angiogenesis and Cancer. Arterioscler Thromb Vasc Biol 2005 May 19.
7.
Berglund M., Thunberg U., Amini R. M., Book M., Roos G., Erlanson M., Linderoth
J., Dictor M., Jerkeman M., Cavallin-Stahl E., Sundstrom C., Rehn-Eriksson S.,
Backlin C., Hagberg H., Rosenquist R. and Enblad G. Evaluation of
immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod
Pathol 2005;18(8):1113-20 Aug.
8.
Berglund P., Stighall M., Jirstrom K., Borgquist S., Sjolander A., Hedenfalk I. and
Landberg G. Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a
novel role reflected in the growth pattern of medullary breast cancers. Cancer Res
2005;65(21):9727-34 Nov 1.
9.
Bjorck E., Ek S., Landgren O., Jerkeman M., Ehinger M., Bjorkholm M., Borrebaeck
C. A., Porwit-MacDonald A. and Nordenskjold M. High expression of cyclin B1
predicts a favorable outcome in patients with follicular lymphoma. Blood
2005;105(7):2908-15 Apr 1.
10.
Bjork-Eriksson T., Ask A. and Glimelius B. The potential of proton beam radiation for
palliation and reirradiation. Acta Oncol 2005;44(8):918-20
11.
Bradlow H. L., Jernstrom H., Sepkovic D. W., Klug T. L. and Narod S. A.
Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16alphahydroxyestrogen metabolites. Mol Genet Metab 2005 Sep 12.
12.
Carlsson C., Baigi A., Killander D. and Satterlund Larsson U. Motives for becoming
and remaining member of patient associations: a study of 1,810 Swedish individuals
with cancer associations. Support Care Cancer 2005;13:1035-1043 Jan 20.
13.
Carlsson C., Nilbert M. and Nilsson K. Patients' involvement in improving cancer
care; experiences in three years of collaboration between members of patient
associations and health care professionals. Patient Education and Counseling
2005;April
14.
Carlsson C., Nilbert M. and Nilsson K. Supporter or obstructer; experiences from
contact person activities among Swedish women with breast cancer. BMC Health
Serv Res 2005;5(1):9 Jan 25.
15.
Charbonnier F., Baert-Desurmont S., Liang P., Di Fiore F., Martin C., Frerot S.,
Olschwang S., Wang Q., Buisine M. P., Gilbert B., Nilbert M., Lindblom A. and
Frebourg T. The 5' region of the MSH2 gene involved in hereditary non-polyposis
colorectal cancer contains a high density of recombinogenic sequences. Hum Mutat
2005;26(3):255-61 Sep.
16.
Engellau J., Bendahl P. O., Persson A., Domanski H. A., Akerman M., Gustafson P.,
Alvegard T. A., Nilbert M. and Rydholm A. Improved prognostication in soft tissue
sarcoma: independent information from vascular invasion, necrosis, growth pattern,
and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol
2005;36(9):994-1002 Sep.
17.
Ericson K. M., Isinger A. P., Isfoss B. L. and Nilbert M. C. Low frequency of
defective mismatch repair in a population-based series of upper urothelial carcinoma.
BMC Cancer 2005;5(1):23 Mar 1.
18.
Falkenback D., Johansson J., Halvarsson B. and Nilbert M. Defective mismatch-repair
as a minor tumorigenic pathway in Barrett esophagus-associated adenocarcinoma.
Cancer Genet Cytogenet 2005;157(1):82-6 Feb.
19.
Francis P., Fernebro J., Eden P., Laurell A., Rydholm A., Domanski H. A., Breslin T.,
Hegardt C., Borg A. and Nilbert M. Intratumor versus intertumor heterogeneity in
gene expression profiles of soft-tissue sarcomas. Genes Chromosomes Cancer
2005;43(3):302-8 Jul.
20.
Garkavij M., Samarzija M., Ewers S. B., Jakopovic M., Tezak S. and Tennvall J.
Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab')2 in patients
with MUC1-positive non-small cell lung cancer. Anticancer Res 2005;25(6C):466371 Nov-Dec.
21.
Glimelius B., Ask A., Bjelkengren G., Bjork-Eriksson T., Blomquist E., Johansson B.,
Karlsson M. and Zackrisson B. Number of patients potentially eligible for proton
therapy. Acta Oncol 2005;44(8):836-49
22.
Gonzalez-Moreno S., Brun E. and Sugarbaker P. H. Lymph node metastasis in
epithelial malignancies of the appendix with peritoneal dissemination does not reduce
survival in patients treated by cytoreductive surgery and perioperative intraperitoneal
chemotherapy. Ann Surg Oncol 2005;12(1):72-80 Jan.
23.
Grafstrom G., Jonsson B. A., El Hassan A. M., Tennvall J. and Strand S. E. Rat Testis
As A Radiobiological In Vivo Model For Radionuclides. Radiat Prot Dosimetry
2005 Jul 26.
24.
Halvarsson B., Lindblom A., Johansson L., Lagerstedt K. and Nilbert M. Loss of
mismatch repair protein immunostaining in colorectal adenomas from patients with
hereditary nonpolyposis colorectal cancer. Mod Pathol 2005 Feb 25.
25.
Hansson B. G., Rosenquist K., Antonsson A., Wennerberg J., Schildt E. B., Bladstrom
A. and Andersson G. Strong association between infection with human papillomavirus
and oral and oropharyngeal squamous cell carcinoma: a population-based case-control
study in southern Sweden. Acta Otolaryngol 2005;125(12):1337-44 Dec.
26.
Hedenfalk I., Glarner N., Kronblad A., Veerla S., Ringner M. and Landberg G.
Microarray-Based Analyses of Hypoxia-Induced Transcriptional Changes in Breast
Cancer Cell Lines. Cancer Genomics & Proteomics 2005;2:83-96
27.
Hindorf C., Linden O., Tennvall J., Wingardh K. and Strand S. E. Evaluation of
methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
Acta Oncol 2005;44(6):579-88
28.
Idvall I., Ringberg A., Anderson H., Akerman M. and Ferno M. Histopathological and
cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast - a
comparison between the primary DCIS and subsequent ipsilateral and contralateral
tumours. The Breast 2005(14):290-297
29.
Ihse I., Andersson R., Ask A., Ewers S. B., Lindell G. and Tranberg K. G.
Intraoperative radiotherapy for patients with carcinoma of the pancreas.
Pancreatology 2005;5(4-5):438-42
30.
Jernstrom H., Borg K. and Olsson H. High follicular phase luteinizing hormone levels
in young healthy BRCA1 mutation carriers: Implications for breast and ovarian cancer
risk. Mol Genet Metab 2005 Aug 2.
31.
Jernstrom H., Loman N., Johannsson O. T., Borg K. and Olsson H. Impact of teenage
oral contraceptive use in a population-based series of early-onset breast cancer cases
who have undergone BRCA mutation testing. Eur J Cancer 2005 Aug 20.
32.
Jernstrom H., Sandberg T., Bageman E., Borg A. and Olsson H. Insulin-like growth
factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal
contraception and is associated with circulating IGF-1 levels: implications for risk of
early-onset breast cancer in young women from hereditary breast cancer families. Br J
Cancer 2005;92(5):857-66 Mar 14.
33.
Jernstrom H., Sellberg G., Borg A. and Olsson H. Differences in IGFBP-3 regulation
between young healthy women from BRCAX families compared with those belonging
to BRCA1/2 families. Eur J Cancer Prev in press 2005
34.
Jirstrom K., Ryden L., Anagnostaki L., Nordenskjold B., Stal O., Torstenson S.,
Chebil G., Jonsson P.-E., Ferno M. and Landberg G. Pathology parameters and
adjuvant tamoxifen response in a randomized pre-menopausal breast cancer trial. J
Clin Pathol 2005;58(11):1135-1142
35.
Johnsson A., Vallon-Christensson J., Strand C., Litman T. and Eriksen J. Gene
expression profiling in chemoresistant variants of three cell lines of different origin.
Anticancer Res 2005;25(4):2661-8 Jul-Aug.
36.
Jonsson G., Bendahl P. O., Sandberg T., Kurbasic A., Staaf J., Sunde L., Cruger D. G.,
Ingvar C., Olsson H. and Borg A. Mapping of a novel ocular and cutaneous malignant
melanoma susceptibility locus to chromosome 9q21.32. J Natl Cancer Inst
2005;97(18):1377-82 Sep 21.
37.
Jonsson G., Naylor T. L., Vallon-Christersson J., Staaf J., Huang J., Ward M. R.,
Greshock J. D., Luts L., Olsson H., Rahman N., Stratton M., Ringner M., Borg A. and
Weber B. L. Distinct genomic profiles in hereditary breast tumors identified by arraybased comparative genomic hybridization. Cancer Res 2005;65(17):7612-21 Sep 1.
38.
Kjellstrom J., Kjellen E. and Johnsson A. In vitro radiosensitization by oxaliplatin and
5-fluorouracil in a human colon cancer cell line. Acta Oncol 2005;44(7):687-93
39.
Kronblad A., Hedenfalk I., Nilsson E., Pahlman S. and Landberg G. ERK1/2
inhibition increases antiestrogen treatment efficacy by interfering with hypoxiainduced downregulation of ERalpha: a combination therapy potentially targeting
hypoxic and dormant tumor cells. Oncogene 2005;24(45):6835-41 Oct 13.
40.
Kuokkanen M., Butzow R., Rasinpera H., Medrek K., Nilbert M., Malander S.,
Lubinski J. and Jarvela I. Lactase persistence and ovarian carcinoma risk in Finland,
Poland and Sweden. Int J Cancer 2005 May 4.
41.
Kvist A., Rovira C., Borg A. and Medstrand P. Promoter usage of BRCA1-IRIS. Nat
Cell Biol 2005;7(4):325-6; author rply 326 Apr.
42.
Laakso M., Loman N., Borg A. and Isola J. Cytokeratin 5/14-positive breast cancer:
true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005;18(10):1321-8
Oct.
43.
Larsson S., Johansson M., Oredsson S. and Holst U. A Markov model approach shows
a large variation in the length of S phase in MCF-7 breast cancer cells. Cytometry A
2005;65(1):15-25 May.
44.
Linden O., Hindorf C., Cavallin-Stahl E., Wegener W. A., Goldenberg D. M., Horne
H., Ohlsson T., Stenberg L., Strand S. E. and Tennvall J. Dose-fractionated
radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Yradiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer
Res 2005;11(14):5215-22 Jul 15.
45.
Linden O., Kurkus J., Garkavij M., Cavallin-Stahl E., Ljungberg M., Nilsson R.,
Ohlsson T., Sandberg B., Strand S. E. and Tennvall J. A novel platform for
radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled
rituximab in patients with refractory B-cell lymphoma. Cancer Biother Radiopharm
2005;20(4):457-66 Aug.
46.
Malander S., Rambech E., Kristoffersson U., Halvarsson B., Ridderheim M., Borg A.
and Nilbert M. The contribution of the hereditary nonpolyposis colorectal cancer
syndrome to the development of ovarian cancer. Gynecol Oncol 2005 Dec 14.
47.
Malekzadeh F., Rose C., Ingvar C. and Jernstrom H. [Natural remedies and hormone
preparations--potential risk for breast cancer patients. A study surveys the use of
agents which possibly counteract with the treatment]. Lakartidningen
2005;102(44):3226-8, 3230-1 Oct 31-Nov 6.
48.
Martensson L., Wang Z., Nilsson R., Ohlsson T., Senter P., Sjogren H. O., Strand S. E.
and Tennvall J. Determining maximal tolerable dose of the monoclonal antibody
BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to
evaluate means to improve radioimmunotherapy. Clin Cancer Res 2005;11(19 Pt
2):7104s-7108s Oct 1.
49.
Moghaddas F., Lidfeldt J., Nerbrand C., Jernstrom H. and Samsioe G. Prevalence of
urinary incontinence in relation to self-reported depression, intake of serotonergic
antidepressants, and hormone therapy in middle-aged women: a report from the
Women's Health in the Lund Area study. Menopause 2005;12(3):318-24 May-Jun.
50.
Nordenskjold B., Rosell J., Rutqvist L. E., Malmstrom P. O., Bergh J., Bengtsson N.
O., Hatschek T., Wallgren A. and Carstensen J. Coronary heart disease mortality after
5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer
Inst 2005;97(21):1609-10 Nov 2.
51.
Phelan C. M., Dapic V., Tice B., Favis R., Kwan E., Barany F., Manoukian S., Radice
P., van der Luijt R. B., van Nesselrooij B. P., Chenevix-Trench G., kConFab, Caldes
T., de la Hoya M., Lindquist S., Tavtigian S. V., Goldgar D., Borg A., Narod S. A. and
Monteiro A. N. Classification of BRCA1 missense variants of unknown clinical
significance. J Med Genet 2005;42(2):138-46 Feb.
52.
Relander T., Johansson M., Olsson K., Ikeda Y., Takeuchi Y., Collins M. and Richter
J. Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or
RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol Ther
2005;11(3):452-9 Mar.
53.
Riisbro R., Christensen I. J., Nielsen H. J., Brunner N., Nilbert M. and Fernebro E.
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic
marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group
collaboration. Int J Biol Markers 2005;20(2):93-102 Apr-Jun.
54.
Rosenquist K., Wennerberg J., Schildt E. B., Bladstrom A., Hansson B. G. and
Andersson G. Use of Swedish moist snuff, smoking and alcohol consumption in the
aetiology of oral and oropharyngeal squamous cell carcinoma. A population-based
case-control study in southern Sweden. Acta Otolaryngol 2005;125(9):991-8 Sep.
55.
Ryden L., Jirstrom K., Bendah P. O., Ferno M., Nordenskjold B., Stal O., Thorstenson
S., Jonsson P.-E. and Landberg G. Tumor-specific expression of VEGFR2 but not
VEGF or HER2 is associated with impaired response to adjuvant tamoxifen in
premenopausala breast cancer. Int J Cancer. J Clin Oncol 2005;23(21):4695-4704
56.
Ryden L., Jonsson P. E., Chebil G., Dufmats M., Ferno M., Jirstrom K., Kallstrom A.
C., Landberg G., Stal O., Thorstenson S. and Nordenskjold B. Two years of adjuvant
tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial
with long-term follow-up. Eur J Cancer 2005;41(2):256-64 Jan.
57.
Saal L. H., Holm K., Maurer M., Memeo L., Su T., Wang X., Yu J. S., Malmstrom P.
O., Mansukhani M., Enoksson J., Hibshoosh H., Borg A. and Parsons R. PIK3CA
Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are
Mutually Exclusive with PTEN Loss in Human Breast Carcinoma. Cancer Res
2005;65(7):2554-2559 Apr 1.
58.
Schoumans J., Staaf J., Jonsson G., Rantala J., Zimmer K. S., Borg A., Nordenskjold
M. and Anderlid B. M. Detection and delineation of an unusual 17p11.2 deletion by
array-CGH and refinement of the Smith-Magenis syndrome minimum deletion to
approximately 650 kb. Eur J Med Genet 2005;48(3):290-300 Jul-Sep.
59.
Strang B. L., Takeuchi Y., Relander T., Richter J., Bailey R., Sanders D. A., Collins
M. K. and Ikeda Y. Human immunodeficiency virus type 1 vectors with alphavirus
envelope glycoproteins produced from stable packaging cells. J Virol
2005;79(3):1765-71 Feb.
60.
Tennvall J., Lundell G. and Wallin G. Tratamiento del cáncer anaplásico de tiroides.
Rev Cancer 2005;19(4):198-203
61.
van den Bent M. J., Afra D., de Witte O., Ben Hassel M., Schraub S., Hoang-Xuan K.,
Malmstrom P. O., Collette L., Pierart M., Mirimanoff R. and Karim A. B. Long-term
efficacy of early versus delayed radiotherapy for low-grade astrocytoma and
oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet
2005;366(9490):985-90 Sep 17-23.
62.
Wang Z., Martensson L., Nilsson R., Bendahl P. O., Lindgren L., Ohlsson T., Sjogren
H. O., Strand S. E. and Tennvall J. Blood pharmacokinetics of various monoclonal
antibodies labeled with a new trifunctional chelating reagent for simultaneous
conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and
biotin before radiolabeling. Clin Cancer Res 2005;11(19 Pt 2):7171s-7177s Oct 1.
Book Chapter
Bratt C. Two-dimensional gel electrophoresis: The state of the art. In Proteomics &
Peptidomics – New technology platforms elucidating biology. In: Marko-Varga G., ed.
Comprehensive analytical Chemistry: Elsevier, Amsterdam 46, 2005: 253-275.
Thesis
1.
Ericson K. Tumors associated with HNPCC: Defective Mismatch Repair and Familial
Risk of Cancer: Lund, 2005.
2.
Vallon-Christersson J. Functional and Molecular Characterization of BRCA1 and
BRCA2 Associated Breast Cancer: Lund, 2005.
3.
Wang Z. RADIOIMMUNOTHERAPY & EXTRACORPOREAL ADSORPTION
Preclinical Studies of the Pharmacokinetics & Biotinylation of
Radioimmunoconjugates in Immunocompetent Rats: Lund, 2005.
4.
Carlsson C. Advocates and Voices. Swedish patient associations, their importance to
individuals with cancer and collaboration with health care.: Lund, 2005.
5.
Gruvberger S. Estrogen receptor alpha and beta in breast cancer - gene expression
profiles and clinical implications: Lund, 2005.
6.
Jonsson G. Genetic characterization of malignant melanoma and breast cancer: Lund,
2005.